Microembolic signal monitoring in patients with <scp>HeartMate</scp> 3 and <scp>HeartWare</scp> left ventricular assist devices: Association with antithrombotic treatment and cerebrovascular events-Reference-Cited by-同舟云学术

Microembolic signal monitoring in patients with HeartMate 3 and HeartWare left ventricular assist devices: Association with antithrombotic treatment and cerebrovascular events

Published:2022-09-27 Issue:2 Volume:47 Page:370-379
ISSN:0160-564X
Container-title:Artificial Organs
language:en
Short-container-title:Artificial Organs

Author:

Ravenberg Kim Kristin¹^ORCID,Gabriel Maria Magdalena¹^ORCID,Leotescu Andrei¹,Tran Anh Thu¹,Grosse Gerrit Maximilian¹^ORCID,Schuppner Ramona¹,Ernst Johanna¹,Lichtinghagen Ralf²,Tiede Andreas³,Werwitzke Sonja³,Bara Christoph Leon⁴,Schmitto Jan Dieter⁴,Weissenborn Karin¹,Hanke Jasmin Sarah⁴^ORCID,Worthmann Hans¹^ORCID

Affiliation:

1. Department of Neurology Hannover Medical School Hannover Germany

2. Institute of Clinical Chemistry Hannover Medical School Hannover Germany

3. Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation Hannover Medical School Hannover Germany

4. Department of Cardiac, Thoracic, Transplantation and Vascular Surgery Hannover Medical School Hannover Germany

Funder

Else Kröner-Fresenius-Stiftung

Publisher

Wiley

Subject

Biomedical Engineering,General Medicine,Biomaterials,Medicine (miscellaneous),Bioengineering

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aor.14409

Reference46 articles.

1. Rise of the Machines — Left Ventricular Assist Devices as Permanent Therapy for Advanced Heart Failure

2. Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH Era

3. A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure

4. Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study

5. Trends in HeartMate 3: What we know so far